The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addit...
Main Authors: | Shuai Liang, Hanyu Wang, Haixia Tian, Zhicheng Xu, Min Wu, Dong Hua, Chengming Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full |
Similar Items
-
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
by: Danilo Rocco, et al.
Published: (2023-09-01) -
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
by: Débora Dummer Meira, et al.
Published: (2023-10-01) -
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
by: Foteinos-Ioannis Dimitrakopoulos, et al.
Published: (2020-05-01) -
A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma
by: Sheng Yu, et al.
Published: (2023-07-01) -
Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis
by: Hesti Platini, et al.
Published: (2022-08-01)